Ubix Therapeutics Collaborates with Yuhan to Develop UBX-103 for Treating Metastatic Castration Resistant Prostate Cancer
Shots:
- Ubix & Yuhan have signed an exclusive license agreement for the development & commercialization of UBX-103 to treat mCRPC
- As per the agreement, Yuhan gains UBX-103’s exclusive global rights to carry out preclinical & clinical studies plus commercialization. Ubix is entitled to receive $3.6M upfront, ~$105M development, regulatory & commercial milestones along with high single-digit royalty. It will receive profit sharing on sublicensing to a 3rd party
- Additionally, UBX-103 showed AR degradation with picomolar DC50, effectiveness against treatment-induced resistance mutations and tumor growth inhibition that are resistant to next-gen. hormonal therapy in the in vivo preclinical model
Ref: Ubix Therapeutics | Image: Ubix Therapeutics
Related News:- Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
